WVE

SEC source: 0001231919-26-001433 · form4-10082026_011038.xml · derivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 64,000

Underlying: Ordinary Shares · 64,000 shares

Expires 2036-10-05

F5 · derivative.exercise_date: Dr. Kolchinsky was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Issuer's 2027 annual meeting of stockholders or October 5, 2027.

F2 · ownership.nature: Dr. Kolchinsky is a Managing Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Kolchinsky's arrangement with the Adviser, Dr. Kolchinsky holds the RSUs and options for the benefit of the Fund. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or shares received upon settlement of the RSUs, or exercise of the options, as applicable, which will offset advisory fees owed by the Fund to the Adviser.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

SEC source: 0001231919-26-001433 · form4-10082026_011038.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 39,515

F1 · shares: Dr. Kolchinsky was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Issuer's 2027 annual meeting of stockholders or October 5, 2027.

F2 · ownership.nature: Dr. Kolchinsky is a Managing Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Kolchinsky's arrangement with the Adviser, Dr. Kolchinsky holds the RSUs and options for the benefit of the Fund. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or shares received upon settlement of the RSUs, or exercise of the options, as applicable, which will offset advisory fees owed by the Fund to the Adviser.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

SEC source: 0001193125-26-417234 · ownership.xml · derivative · entry 2

CORRIGAN MARK · CIK 0001250661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,000

Underlying: Common Stock · 64,000 shares

Expires 2036-10-05

F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417234 · ownership.xml · nonDerivative · entry 1

CORRIGAN MARK · CIK 0001250661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,515

F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417235 · ownership.xml · derivative · entry 3

TAKANASHI KEN · CIK 0001657768 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,000

Underlying: Common Stock · 64,000 shares

Expires 2036-10-05

F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417235 · ownership.xml · nonDerivative · entry 1

TAKANASHI KEN · CIK 0001657768 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,779

F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417236 · ownership.xml · derivative · entry 2

Tan Aik Na · CIK 0001821285 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,000

Underlying: Common Stock · 64,000 shares

Expires 2036-10-05

F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417236 · ownership.xml · nonDerivative · entry 1

Tan Aik Na · CIK 0001821285 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,668

F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417237 · ownership.xml · derivative · entry 3

Verdine Gregory L. · CIK 0001572315 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,000

Underlying: Common Stock · 64,000 shares

Expires 2036-10-05

F3 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417237 · ownership.xml · nonDerivative · entry 1

Verdine Gregory L. · CIK 0001572315 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,917

F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417232 · ownership.xml · derivative · entry 2

HENRY CHRISTIAN O · CIK 0001263805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,000

Underlying: Common Stock · 64,000 shares

Expires 2036-10-05

F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417232 · ownership.xml · nonDerivative · entry 1

HENRY CHRISTIAN O · CIK 0001263805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,400

F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417231 · ownership.xml · derivative · entry 2

Wagner Heidi L · CIK 0001655029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,000

Underlying: Common Stock · 64,000 shares

Expires 2036-10-05

F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417231 · ownership.xml · nonDerivative · entry 1

Wagner Heidi L · CIK 0001655029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,630

F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417233 · ownership.xml · derivative · entry 2

Rawcliffe Adrian · CIK 0001555851 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,000

Underlying: Common Stock · 64,000 shares

Expires 2036-10-05

F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-417233 · ownership.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,700

F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC source: 0001193125-26-349962 · ownership.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

F2 · price: The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $5.16 to $5.42 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001193125-26-349963 · ownership.xml · derivative · entry 3

Wagner Heidi L · CIK 0001655029 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 7,000 shares

Expires 2026-08-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

F2 · derivative.exercise_date: These stock options are fully vested.

SEC source: 0001193125-26-349963 · ownership.xml · nonDerivative · entry 2

Wagner Heidi L · CIK 0001655029 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,930

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

SEC source: 0001193125-26-349963 · ownership.xml · nonDerivative · entry 1

Wagner Heidi L · CIK 0001655029 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,930

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

SEC source: 0001193125-26-349961 · ownership.xml · nonDerivative · entry 1

TAKANASHI KEN · CIK 0001657768 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,079

F1 · shares: On August 11, 2026, the reporting person sold 3,864 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan.

F2 · price: The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.01 to $6.03 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001193125-26-349960 · ownership.xml · nonDerivative · entry 1

Tan Aik Na · CIK 0001821285 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,968

F1 · kind: On August 11, 2026, the reporting person sold 432 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan.

SEC source: 0001231919-26-000297 · form4-03312026_120347.xml · nonDerivative · entry 4

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 26,975,505

F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.305 to $6.665 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001231919-26-000297 · form4-03312026_120347.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 26,004,414

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.09 to $6.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001231919-26-000297 · form4-03312026_120347.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 23,508,791

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.365 to $6.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001231919-26-000297 · form4-03312026_120347.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 23,157,567

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.365 to $6.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001193125-26-126276 · ownership.xml · derivative · entry 3

TAKANASHI KEN · CIK 0001657768 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,901,348 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026.

F1 · date: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026.

F1 · kind: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026.

F2 · shares: Includes (i) 2,100,000 shares held by SNBL USA and (ii) 1,801,348 shares held by SNBL.

F1 · derivative.exercise_date: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026.

F1 · derivative.expiration_date: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026.

F4 · ownership.nature: Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL.

SEC source: 0001193125-26-126276 · ownership.xml · nonDerivative · entry 1

TAKANASHI KEN · CIK 0001657768 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 9,606,408

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026.

F1 · kind: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026.

F2 · shares: Includes (i) 2,100,000 shares held by SNBL USA and (ii) 1,801,348 shares held by SNBL.

F3 · balance_after: Includes an aggregate of (i) 6,107,593 shares held by SNBL USA and (ii) 3,498,815 shares held by SNBL.

F4 · ownership.nature: Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL.

SEC source: 0001193125-26-083712 · ownership.xml · derivative · entry 6

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,175

Underlying: Ordinary Shares · 15,294 shares

Expires 2033-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.

SEC source: 0001193125-26-083712 · ownership.xml · derivative · entry 5

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,200

Underlying: Ordinary Shares · 17,900 shares

Expires 2034-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028.

SEC source: 0001193125-26-083712 · ownership.xml · nonDerivative · entry 4

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,867

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.

SEC source: 0001193125-26-083712 · ownership.xml · nonDerivative · entry 3

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,161

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.

SEC source: 0001193125-26-083712 · ownership.xml · nonDerivative · entry 2

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,867

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.

F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001193125-26-083712 · ownership.xml · nonDerivative · entry 1

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,767

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.

SEC source: 0001193125-26-047319 · ownership.xml · nonDerivative · entry 2

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,867

F2 · kind: On February 9, 2026, the reporting person sold 1,883 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.

SEC source: 0001193125-26-047314 · ownership.xml · nonDerivative · entry 2

Vargeese Chandra · CIK 0001657675 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 408,246

F3 · kind: On February 9, 2026, the reporting person sold 3,228 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.

SEC source: 0001193125-26-047322 · ownership.xml · nonDerivative · entry 2

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,520

F2 · kind: On February 9, 2026, the reporting person sold 10,480 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.

SEC source: 0001193125-26-047323 · ownership.xml · nonDerivative · entry 2

Moran Kyle · CIK 0001657765 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,385

F3 · kind: On February 9, 2026, the reporting person sold 3,588 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.

SEC source: 0001193125-26-047319 · ownership.xml · derivative · entry 3

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,500

Underlying: Ordinary Shares · 232,500 shares

Expires 2036-02-05

F3 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.

SEC source: 0001193125-26-047319 · ownership.xml · nonDerivative · entry 1

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,750

F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.

SEC source: 0001193125-26-047314 · ownership.xml · derivative · entry 3

Vargeese Chandra · CIK 0001657675 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 273,750

Underlying: Ordinary Shares · 273,750 shares

Expires 2036-02-05

F4 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.

SEC source: 0001193125-26-047314 · ownership.xml · nonDerivative · entry 1

Vargeese Chandra · CIK 0001657675 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 411,474

F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.

F2 · balance_after: Includes 3,162 ordinary shares acquired on July 15, 2025, and January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.

SEC source: 0001193125-26-047322 · ownership.xml · derivative · entry 3

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Ordinary Shares · 1,000,000 shares

Expires 2036-02-05

F3 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.

SEC source: 0001193125-26-047322 · ownership.xml · nonDerivative · entry 1

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 286,000

F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.

SEC source: 0001193125-26-047323 · ownership.xml · derivative · entry 3

Moran Kyle · CIK 0001657765 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 273,750

Underlying: Ordinary Shares · 273,750 shares

Expires 2036-02-05

F4 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.

SEC source: 0001193125-26-047323 · ownership.xml · nonDerivative · entry 1

Moran Kyle · CIK 0001657765 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,973

F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.

F2 · balance_after: Includes 1,983 ordinary shares acquired on January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.

SEC source: 0001193125-26-005195 · ownership.xml · derivative · entry 4

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 9,375 shares

Expires 2032-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: These share options are fully vested.

SEC source: 0001193125-26-005195 · ownership.xml · nonDerivative · entry 3

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,000

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.

F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $16.61 to $16.79 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001193125-26-005195 · ownership.xml · nonDerivative · entry 2

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,295

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.

F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.56 to $16.54 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001193125-26-005195 · ownership.xml · nonDerivative · entry 1

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.